Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

  1. Trigo, J.
  2. Subbiah, V.
  3. Besse, B.
  4. Moreno, V.
  5. López, R.
  6. Sala, M.A.
  7. Peters, S.
  8. Ponce, S.
  9. Fernández, C.
  10. Alfaro, V.
  11. Gómez, J.
  12. Kahatt, C.
  13. Zeaiter, A.
  14. Zaman, K.
  15. Boni, V.
  16. Arrondeau, J.
  17. Martínez, M.
  18. Delord, J.-P.
  19. Awada, A.
  20. Kristeleit, R.
  21. Olmedo, M.E.
  22. Wannesson, L.
  23. Valdivia, J.
  24. Rubio, M.J.
  25. Anton, A.
  26. Sarantopoulos, J.
  27. Chawla, S.P.
  28. Mosquera-Martinez, J.
  29. D'Arcangelo, M.
  30. Santoro, A.
  31. Villalobos, V.M.
  32. Sands, J.
  33. Paz-Ares, L.
  34. Show all authors +
Journal:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Year of publication: 2020

Volume: 21

Issue: 5

Pages: 645-654

Type: Article

DOI: 10.1016/S1470-2045(20)30068-1 GOOGLE SCHOLAR

Sustainable development goals